Navigation Links
ERT Leader Recognized for Exemplifying Values, Commitment to Improving Patient Health
Date:8/3/2020

ERT, the global leader in clinical endpoint data collection, today announced Jim Corrigan, President and CEO has been named one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice. Representing a broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired their colleagues and affected positive changes in their organizations.

Jim is recognized for his dedication to supporting the industry during a time of significant change by exemplifying his core values which include ensuring employee well-being, instilling a culture of accountability and trust, and an unwavering focus on helping ERT’s customers develop new treatments to improve the health of patients worldwide.

Jim has driven significant advancements in clinical trial methodologies that help global biopharmaceutical companies bring new treatments to patients through more efficient and effective data collection. Since COVID-19 stay-home mandates have interrupted some important clinical development programs, Jim has led ERT to accelerate its delivery of virtual data collection tools, ensuring patient safety and enabling clinical trial continuity regardless of their physical access to investigative sites.

“Jim’s ability to inspire innovative thinking enables ERT to continually exceed customers’ expectations and deliver the solutions they need to meet their complex needs,” said Eran Broshy, Chairman of ERT’s Board of Directors. “We’re very proud of his accomplishments and applaud him – as well as all of the individuals being recognized – for this well-deserved recognition.”

For more information, visit ert.com

About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly - and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.

Read the full story at https://www.prweb.com/releases/ert_leader_recognized_for_exemplifying_values_commitment_to_improving_patient_health/prweb17295707.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Genomics Data Management Leader Annai Systems Offers Shortcut to Analysis
2. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
3. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
4. Dominion Diagnostics to Sponsor 2013 Addiction Professional Panel Series as Thought Leadership Partner
5. UCSB summit draws key leaders to discuss innovations in energy efficiency science and technology
6. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
7. NSF International Promotes Three Leaders and Scientific Experts to Key Global Positions
8. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
9. NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
10. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
11. Israel’s BioEnergy Leaders Meet for Two Days of Deliberations with U.S. Government Counterparts - Following Wednesday White House Briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... ... combine up to three different materials for use with CRM, neurostimulation, vascular, and ... three materials to meet specific design requirements, performance, and cost criteria; especially where ...
(Date:7/31/2020)... FRANCISCO (PRWEB) , ... July ... ... provider of cloud-based software for the life sciences industry, today announced the ... presentation platform designed specifically for Medical Science Liaisons (MSLs) and other field ...
(Date:7/18/2020)... Ohio (PRWEB) , ... July 16, 2020 , ... ... data solutions to aid in the early detection and prevention of high-burden diseases, ... to enable US-based hospitals and healthcare organizations to utilize existing data in order ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency ... led by Dr MA has been using the zebrafish model to investigate the ...
Breaking Biology Technology:
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is a critical stage in ... COVID cure or vaccine, the global economic downturn will only increase price pressures overall ... away and capturing full value from every product launch is critical. However, history shows ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... (MBS) has announced a publication detailing the use of its revolutionary NEXTGENPCR ... chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast one-step RT-PCR ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical ... clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... in hospitalized patients with severe COVID-19. This is the first study of an ...
Breaking Biology News(10 mins):